Glaucoma is a leading cause of blindness worldwide and is the second most frequent cause of non-accidental blindness in industrialised countries. [1] [2] [3] [4] [5] [6] [7] [8] 13, 14 In glaucoma, the optic nerve is progressively damaged, causing defects in the visual field, usually asymptomatic until the central vision is affected. 10 Primary open angle glaucoma (POAG), the most common form of glaucoma observed in developed western countries, 9 is associated with intraocular pressure (IOP) increased to a level likely to interfere with the health of the optic nerve. In normal-pressure glaucoma (NPG), there is no increase of IOP.
In 2000, the prevalence of glaucoma in the UK was estimated to be as high as 3.3% in people over 40 years of age, and up to 5% in those aged 80 years and over. 16 In Italy, approximately 50,000 people are visually handicapped by glaucoma, while an estimated 540,000 people over 40 suffer from glaucoma, half of whom are undiagnosed. 17 In Germany, glaucoma was reported as the third leading cause of blindness (1.6/100,000), and an estimated one-fifth of all cases of legal blindness in persons aged 75 and older were due to glaucoma (22.8/100,000). 18 Approximately 500,000 patients in France are followed and treated for POAG, with a similar number of cases undiagnosed. 19, 20 Glaucoma costs the US healthcare system an estimated US$2.5 billion annually: US$1.9 billion in direct costs and US$0.6 billion in indirect costs. 20 The annual direct medical cost of treating newly diagnosed open-angle glaucoma was estimated at US$1,055 per patient. 21 Standard treatment costs were put at FFr2,289 per patient (France) and £380 (UK). 22 Several international retrospective chart reviews have considered the economic burden of the management of glaucoma, particularly in the first two years after diagnosis. 20, 21 However, limited data exist on resource consumption as a function of disease severity and, in particular, of treating advanced-stage disease. A study in Canada showed an increase in direct costs with more severe damage. 23 We have published data on resource utilisation and direct medical costs associated with the long-term management of glaucoma of different severities in five European countries (Austria, France, Germany, Italy and the UK), and showed that resource consumption and direct costs increase as disease severity worsens. 24 In our study, data collected included patient demographics, glaucoma risk factors, number of ophthalmologist visits, number and type of glaucoma medications and surgeries and visual field results. All clinical tests documented in the charts were recorded. Essential examinations, such as IOP assessments, optic nerve assessments, retinal or macular examinations, slit-lamp examinations and gonioscopies, as well as more specialised tests, such as diurnal curves of IOP measurements, retinal nerve fibre thickness assessments and optic disc photographs, were considered. The results can be summarised simply in one graph (see Figure 1 ). In examining medical resource consumption associated with a chronic, potentially blinding disease such as glaucoma, one may postulate that as disease severity worsens, greater medical effort will be prompted by the desire of physicians to slow disease progression, as well as by increased patient concern. In particular, as glaucoma is often asymptomatic in the early phases, resulting in delayed diagnosis, a consequently increased medical vigilance after diagnosis is likely as the disease progresses.
Patients with end-stage disease -stage 5 in Figure 1 Moreover, low vision care, vision rehabilitation services and non-physician resources to which patients with end-stage disease may be referred for further management were not calculated as direct medical costs.
Data from our study 24 Carlo E Traverso is Associate Professor at the University Eye Clinic in Genoa, where he also directs glaucoma and stem cell research, and Head of the Glaucoma and Cornea Clinical Unit at the University of Genoa Medical School. He is the author of over 250 articles, chapters and monographs, the editor of four books and the recipient of the Italian Ophthalmological Society Prize and the American Academy of Ophthalmology Honor Award.
E: mc8620@mclink.it E U R O P E A N O P H T H A L M I C R E V I E W 2 0 0 7
The Cost of Managing Glaucoma Increases with Worsening of Disease Stage disease stage. Since topical ocular hypotensive medications are as effective as early surgery in delaying the rate of progression, 25 the majority of physicians are likely to offer medication therapy before advising surgery. In general, preventing patients from progressing from early to severe stages will result in a projected decrease of between 30 and 50% of the costs, [21] [22] [23] 26, 27 but there are methodological limitations. Glaucoma progression may be measured by ophthalmologists using visual field examination, optic nerve head clinical assessment or both. 11 Visual field examination is the standard of care to evaluate disease progression, and for clinicians it represents the need to adjust the management of the patient. 10, 26, 28, 29 There are limitations in interpreting data retrospectively collated from the previous five to seven years, i.e. the number of years for which a patient may have been in his or her baseline stage before the study entry could not be controlled, and patients with at least five years of followup data may differ from patients who do not seek persistent care for glaucoma for the same time period, thus creating a potential selection bias. Office visits Glaucoma exams Visual fields
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